A place-of-care approach to CAR-T cell manufacturing

CAR-T is a multi-step, gene-modified cell therapy process used to treat refractory hematologic malignancies. Since the historic FDA approval of Kymriah for the treatment of B-cell leukemia, CART has provided a durable treatment option for heavily pre-treated leukemia, lymphoma and multiple myeloma patients. This therapy is unique among other drug types in that the final product is a manipulated version of the patients’ own T-cells. Blood is collected from patients, T-cells are isolated and genetically engineered with a synthetic CAR gene. Once modified, the T-cells are infused back into the patient’s bloodstream and the CAR protein enables the T-cells to bind and kill cancer cells. In this sense, CAR-T is a living drug that delivers the potential for long-term remission after a single treatment.